ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Cognitive Dysfunction
Alzheimer Disease

Multiple Sclerosis (MS) trials near Paris, Île-de-France, FRA:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Active, not recruiting
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Le Kremlin-Bicêtre, France and 50 other locations

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Active, not recruiting
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Créteil, France and 36 other locations

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Active, not recruiting
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Le Kremlin-Bicêtre, France and 72 other locations

Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnorma...

Enrolling
Multiple Sclerosis, Relapsing-Remitting
Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
Drug: Placebo 4 mL Solution for Injection

Phase 2

University Hospital, Strasbourg, France

Paris, France and 4 other locations

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Le Kremlin-Bicêtre, Val De Marne, France and 65 other locations

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Le Kremlin-Bicêtre, France and 105 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Suresnes, France and 249 other locations

persons with Multiple Sclerosis, including the walking ability....

Begins enrollment in 1 month
Multiple Sclerosis
Device: EXOPULSE Suit in Sham mode
Device: EXOPULSE Suit in Active mode
Otto Bock Healthcare (Ottobock)

Créteil, France and 10 other locations

relapse rate and lesion load accumulation in the relapsing form of multiple sclerosis (RMS). This therapeutic agent also showed for ...

Enrolling
Primary Progressive Multiple Sclerosis
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Assistance Publique - Hôpitaux de Paris

Paris, France

ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be included on a voluntary basis. The inves...

Active, not recruiting
Multiple Sclerosis
Device: Actimyo
University Hospital Center (CHU) of Liege

Paris, France and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems